Abstract
Eleven patients with metastatic renal cell carcinoma received combination therapy with 5-fluorouracil (5-FU), Cisplatin (CDDP) and Interferon alpha-2b (IFN alpha-2b). For 5 days, 500 mg of 5-FU was administered by continuous intravenous infusion daily; 20 mg/m2 CDDP was injected intravenously daily for 5 days, and 3 or 6 million units of IFN alpha-2b was administered intramuscularly twice a week for 3 weeks. This treatment cycle was repeated every 3 weeks. One of 11 patients achieved a partial response, and the response rate was 9%. High grade toxicities (WHO grade 3 or 4), nausea and vomiting (27%), leukocytopenia (9%), anemia (9%) and thrombocytopenia (18%) were seen. One of the reasons that this regimen dose not appear to be effective may be the low total dose of 5-FU for renal cell carcinoma.
MeSH terms
-
Aged
-
Aged, 80 and over
-
Anemia / chemically induced
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Renal Cell / therapy*
-
Cisplatin / administration & dosage
-
Cisplatin / adverse effects
-
Drug Administration Schedule
-
Female
-
Fluorouracil / administration & dosage
-
Fluorouracil / adverse effects
-
Humans
-
Infusions, Intravenous
-
Injections, Intramuscular
-
Interferon alpha-2
-
Interferon-alpha / administration & dosage
-
Interferon-alpha / adverse effects
-
Kidney Neoplasms / therapy*
-
Leukopenia / chemically induced
-
Male
-
Middle Aged
-
Nausea / chemically induced
-
Recombinant Proteins
-
Thrombocytopenia / chemically induced
-
Vomiting / chemically induced
Substances
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins
-
Cisplatin
-
Fluorouracil